The SPC notes that a moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformations or foetal/neonatal toxicity associated with tenofovir disoproxil fumarat (TDF). Animal studies do not indicate reproductive toxicity. Therefore use of TDF may be considered during pregnancy, if necessary.